Table 4

Base case and one-way deterministic sensitivity analyses

ΔCosts

ΔQALYs

ICURs, $/QALY

Values

B vs A

C vs A

B vs A

C vs A

B vs A

C vs A

Base case

$58,488

$77,004

$0.163

$0.134

$358,088

$575,540

Remission rate in responders

Usual care

0.054

$58,049

$76,557

0.181

0.151

$320,893

$505,803

0.238

$58,937

$77,446

0.146

0.117

$402,860

$663,307

5 mg/kg infliximab

0.174

$57,360

$76,880

0.121

0.100

$476,059

$768,537

0.378

$59,592

$77,143

0.203

0.166

$293,330

$464,724

Remission rate in non-responders induced

Adalimumab

0.061

$58,054

$76,876

0.123

0.120

$471,182

$641,097

0.139

$58,923

$77,133

0.200

0.146

$295,032

$526,848

Early IPAA

0.108

$72,853

$95,814

0.254

0.215

$286,943

$446,029

0.475

$47,476

$61,931

0.104

0.082

$457,710

$753,220

Utilities

Remission

0.720

$58,499

$77,007

0.111

0.087

$527,236

$889,227

0.858

$58,499

$77,007

0.214

0.180

$273,081

$428,676

Surgical remission

0.598

$58,499

$77,007

0.197

0.167

$296,939

$462,473

0.762

$58,499

$77,007

0.130

0.101

$451,163

$761,873

Surgical complications

0.399

$58,499

$77,007

0.185

0.155

$316,155

$497,122

0.580

$58,499

$77,007

0.142

0.113

$412,327

$681,998

Strategy A: 'usual care'; Strategy B: '5 mg/kg infliximab +adalimumab'; Strategy C: '5 mg/kg and 10 mg/kg infliximab + adalimumab'. IPAA: one-stage ileal-pouch anal anastomosis; UC: ulcerative colitis.

Xie et al. Cost Effectiveness and Resource Allocation 2009 7:20   doi:10.1186/1478-7547-7-20